AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026
Key Highlights
- ➤ABBV-295 half-life 10.7-12.3 days supports beyond-weekly dosing evaluation
- ➤ABBV-295 weekly cohorts cut body weight 7.8%-9.8% at Week 12
- ➤ABBV-295 every-other-week regimen reduced body weight 9.7% at Week 13
- ➤ABBV-295 monthly regimen reduced body weight 7.9% at Week 13
- ➤AbbVie (ABBV) plans Phase 2 development for chronic weight management
Expert Statements
Primal Kaur, Senior vice president, global development of immunology, neuroscience, eye care and specialty at AbbVie
“As the obesity treatment landscape evolves, we remain focused on bringing forth differentiated approaches that help expand available therapeutic options for people living with this complex disease.”
Primal Kaur, Senior vice president, global development of immunology, neuroscience, eye care and specialty at AbbVie
“These detailed results showed meaningful weight loss alongside a half-life that could support dosing less frequently than once weekly, and they reinforce the scientific rationale for targeting the amylin pathway.”
Primal Kaur, Senior vice president, global development of immunology, neuroscience, eye care and specialty at AbbVie
“We look forward to advancing ABBV-295 into Phase 2 development.”
Juan Pablo Frías, Medical Director and Primary Investigator at Los Angeles Institute for Metabolic Research and study author
“Obesity is a chronic disease that requires long-term treatment, and the practical realities of therapy, such as how often someone has to take medication and how they feel while doing it, matter a great deal for patients to stay on treatment.”
Juan Pablo Frías, Medical Director and Primary Investigator at Los Angeles Institute for Metabolic Research and study author
“In this Phase 1 study, ABBV-295 demonstrated meaningful weight loss across multiple dosing regimens and a pharmacokinetic profile supportive of further evaluation of extended dosing intervals.”
Juan Pablo Frías, Medical Director and Primary Investigator at Los Angeles Institute for Metabolic Research and study author
“Together, these findings support continued development of this investigational therapy for patients.”
AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026 PR Newswire
* Detailed findings, to be presented in a short oral presentation, demonstrated an approximately 11- to 12-day half-life and dose-proportional increases in plasma exposure, supporting evaluation of ABBV-295 at dosing intervals beyond weekly administration, including every-other-week and monthly regimens * ABBV-295 showed meaningful body weight reduction and a favorable tolerability profile at all evaluated dose levels, with topline results announced earlier this year * Findings support advancement of ABBV-295 — a non-incretin, amylin-based mechanism — into Phase 2 development for chronic weight management NORTH CHICAGO, Ill., Sept. 30, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that detailed results from the multiple ascending dose (MAD) part of its Phase 1 study evaluating ABBV-295 will be presented in a short oral presentation at the European Association for the Study of Diabetes (EASD) 2026 Annual Meeting (Milan, Italy; September 28 – October 2). The study evaluated the tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous ABBV-295, an investigational long-acting amylin analog, in adults with a mean body mass index (BMI) of less than 30 kg/m(2).
Get started
Create a free account to read the full story.